Sigyn Therapeutics (SIGY) Operating Income (2017 - 2025)
Sigyn Therapeutics (SIGY) posted Operating Income of -$386529.0 for Q3 2025, up 17.67% sequentially from -$469513.0 in Q2 2025, and up 52.19% YoY from -$253979.0 in Q3 2024.
Sigyn Therapeutics (SIGY) Operating Income (2017 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Operating Income for 9 years, with the latest figure at -$386529.0 in Q3 2025.
- Quarterly Operating Income rose 52.19% year-over-year to -$386529.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$1.9 million (up 31.84% YoY) and the FY2024 annual result came in at -$2.5 million, down 2.6% from the prior year.
- Operating Income improved to -$386529.0 in Q3 2025 per SIGY's latest filing, from -$469513.0 in the prior quarter.
- Over five years, Operating Income peaked at -$386529.0 in Q3 2025 and troughed at -$808458.0 in Q3 2024.
- A 5-year average of -$554323.4 and a median of -$546059.0 in 2025 frame the typical range for Operating Income.
- The sharpest annual moves came in 2021 and 2025: Operating Income slumped 182.48% in 2021, then jumped 52.19% in 2025.
- Over 5 years, Operating Income stood at -$590939.0 in 2021, then gained by 20.2% to -$471588.0 in 2022, then plunged by 52.09% to -$717236.0 in 2023, then surged by 33.35% to -$478010.0 in 2024, then gained by 19.14% to -$386529.0 in 2025.
- According to Business Quant data, Operating Income over the past three periods registered -$386529.0, -$469513.0, and -$546059.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | -386,529.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -386,529.00 |
| Jun 30, 2025 | -469,513.00 |
| Mar 31, 2025 | -546,059.00 |
| Dec 31, 2024 | -478,010.00 |
| Sep 30, 2024 | -808,458.00 |
| Jun 30, 2024 | -602,805.00 |
| Mar 31, 2024 | -629,972.00 |
| Dec 31, 2023 | -717,236.00 |
| Sep 30, 2023 | -642,814.00 |
| Jun 30, 2023 | -574,009.00 |
| Mar 31, 2023 | -521,258.00 |
| Dec 31, 2022 | -471,588.00 |
| Sep 30, 2022 | -533,647.00 |
| Jun 30, 2022 | -532,795.00 |
| Mar 31, 2022 | -609,236.00 |
| Dec 31, 2021 | -590,939.00 |
| Sep 30, 2021 | -573,363.00 |
| Jun 30, 2021 | -441,818.00 |
| Mar 31, 2021 | -402,096.00 |
| Dec 31, 2020 | -344,567.00 |